🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
LLY
NYSE
🇺🇸 US
Eli Lilly and Company
Pharmaceuticals
16Score
DipBuster Score™
$1,146.90
$32.21 (-2.73%)
Live price · Source: Yahoo
52-Week Position
$623.78
84% of range
$1,249.45
Beta
0.506
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.506
52W High$1,249.45
52W Low$623.78
DipBuster Brief
Key signals at a glance
Zone: Consider Trimming
Bearish
Near 52-Week High — Asymmetric Risk
At 84% of its annual range the stock is close to its peak. New buyers face limited upside and meaningful downside if sentiment shifts.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position84% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.506
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Eli Lilly and Company (LLY), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-06-15 | Luciano Juan R | BUY | 14 |
| 2026-06-15 | Fyrwald J Erik | BUY | 9 |
| 2026-06-15 | Alvarez Ralph | BUY | 11 |
| 2026-06-15 | Sulzberger Gabrielle | BUY | 4 |
| 2026-06-10 | Yuffa Ilya | SELL | 2,500 |
| 2026-05-18 | Luciano Juan R | BUY | 16 |
| 2026-05-18 | Fyrwald J Erik | BUY | 10 |
| 2026-05-18 | Alvarez Ralph | BUY | 13 |
| 2026-05-18 | Sulzberger Gabrielle | BUY | 5 |
| 2026-05-06 | Lilly Endowment Inc | SELL | 2,208 |
Valuation
P/E RatioN/A
Market CapN/A
Beta0.506
Dividend/yrNone
52W High$1,249.45
52W Low$623.78
52-Week Range
$623.78Now$1,249.45
84% through annual range
From 52W High−8.2%
From 52W Low+83.9%
📖 Plain English Summary
Eli Lilly and Company is at 84% of its 52-week range. Beta 0.506 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for LLY
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — LLY
Heuristic · balance sheet, insider filings, price data, academic research
Eli Lilly and Company — DipBuster Score 16/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Eli Lilly and Company free
Add LLY to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Trading 212
Commission-free investing. ISA and GIA available. FCA regulated.
Free share worth up to £100 when you sign up
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
7/25
Momentum & Volume
4/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
2
/100 · NEUTRAL
dip depth
1/25
oversold rsi
0/25
mean reversion
1/15
insider zone
0/25
capitulation
0/10
Insiders' avg buy price: $649.39 — marked 🟡 on the chart above.
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 16/100
📉
Weak momentum — price has been struggling lately.
Company Profile
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite o…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
David A. Ricks
Staff
50,000 employees
Website